OBJECTIVES: To elicit utility values for CML chronic phase health states (i.e. molecular response (MR), complete molecular response (CMR) [i.e. undetectable disease on treatment], treatment-free remission (TFR) and re-appearance of detectable disease (RDD) [i.e. relapse from treatment-free remission to molecular response requiring treatment]) from the general public in the UK. METHODS: Interviewer-administered time trade-off (TTO) and standard gamble (SG) utilities were elicited for four CML-related health states from a random sample of 235 members of the general public in the UK, using health state descriptions validated by clinicians and members of the general public. RESULTS: Respondents’ mean age was 61 years and 47% were female. Mean utilities were: 0.90 (TTO) and 0.72 (SG) for RDD, 0.94 (TTO) and 0.80 (SG) for MR, 0.96 (TTO) and 0.85 (SG) for CMR and 0.97 (TTO) and 0.87 (SG) for TFR. SG values were all significantly lower than TTO values (p <0.001). TTO values for TFR and CMR were significantly different from that for RDD (p = 0.002). The SG value for TFR was significantly different from that for MR and RDD (p <0.001). Additionally, the SG value for MR was significantly different from that for CMR (p = 0.02) and RDD (p <0.001). Respondents’ preference values for any of the states were not affected by their demographics, except SG values elicited from males which were ~0.08 higher than those from females (p <0.05). CONCLUSIONS: These findings suggests that level of response to treatment impacts on patients’ health-related quality of life in CML. Health states associated with a better outcome (e.g. TFR) were associated with a higher preference value than states with a poorer outcome (e.g. RDD). These utility values can be used to estimate quality-adjusted life years associated with different treatment options.